NDAOPHTHALMICSOLUTION
Approved
Sep 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
5/8 — Partial
OMLONTI (omidenepag isopropyl) by ExThera Medical is ep2 receptor agonist which decreases intraocular pressure (iop). Approved for elevated intraocular pressure (iop) in patients with open-angle glaucoma, ocular hypertension, hypertension. First approved in 2022.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OMLONTI is an ophthalmic solution containing omidenepag isopropyl, an EP2 receptor agonist approved by the FDA in September 2022 for reducing intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. The drug works by lowering IOP through an EP2 receptor mechanism, reducing the risk of optic nerve damage and visual field loss associated with elevated intraocular pressure.
Peak12.9 years to LOE
OMLONTI is in peak commercial phase post-FDA approval with strong patent protection through 2039, indicating sustained market opportunity and team growth for the next 3-5 years.
Mechanism of Action
EP2 receptor agonist which decreases intraocular pressure (IOP). The exact mechanism of action is unknown at this time. Elevated IOP represents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss.
Worked on OMLONTI at ExThera Medical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.